NCT03712540View on ClinicalTrials.gov

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 6, 2018

Primary Completion Date

November 8, 2018

Study Completion Date

November 8, 2018

Conditions
Healthy Participants
Interventions
DRUG

BMS-986278

Oral administration 30 mg

DRUG

Rifampin

Oral administration 600 mg

Trial Locations (1)

66219

PRA Health Science KK, Lenexa

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY